AbbVie ( ABBV) was upgraded by TheStreet's Quant Ratings service Tuesday. Let's see if the charts and indicators are on the same page as the quantitative approach.
In the daily bar chart of ABBV, below, I can see a mixed picture. Prices have rallied from lows in June and July. ABBV trades above the rising 50-day moving average line but below the 200-day moving average line.
The trading volume has not increased on the recent rally. The On-Balance-Volume (OBV) line has been drifting lower since December and suggests that sellers of ABBV have been more aggressive than buyers.
The Moving Average Convergence Divergence (MACD) oscillator is above the zero line but correcting to the downside. 
In the weekly Japanese candlestick chart of ABBV, below, I see a mixed longer-term picture. The shares have moved sideways to lower since early 2022. Prices are trading below the cresting 40-week moving average line.
The weekly OBV line has been in a long sideways trend since early 2022. The MACD oscillator has been weak since early 2022 and is below the zero line.
In this daily Point and Figure chart of ABBV, below, I can see an upside price target in the $192 area.
In this second Point and Figure chart of ABBV, below, I used weekly price data. Here I see the same $192 price target but that strength above $166 refreshes the uptrend.
Bottom-line strategy: A quantitative upgrade gets my attention and bullish charts keep it. Traders could go long ABBV on strength above $166.
